scholarly journals High Dose Rate Brachytherapy as a Treatment Option in Endobronchial Tumors

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Ali Hosni ◽  
Andrea Bezjak ◽  
Alexandra Rink ◽  
Kasia Czarnecka ◽  
Andrew McPartlin ◽  
...  
Keyword(s):  
Dose Rate ◽  
External Beam Radiotherapy ◽  
Late Toxicity ◽  
Complete Response ◽  
High Dose Rate ◽  
High Dose ◽  
Subjective Response ◽  
Short Term ◽  
Curative Intent ◽  
Promising Treatment

Purpose. To report our experience with high dose rate endobronchial brachytherapy (HDR-EBBT) and to assess its efficacy and tolerability with possibility of its use in selected cases with curative intent. Method. Retrospective review of patients with endobronchial tumors treated at our institution in 2007–2013 with HDR-EBBT. Subjective response and treatment related toxicity were extracted from patients’ records. Clinical response was evaluated by chest CT +/− bronchoscopy 2-3 months after treatment. Local control (LC) and overall survival (OS) were analyzed. Results. Overall 23 patients were identified. Ten patients were treated with curative intent, in 8 of them HDR-EBBT was combined with external beam radiotherapy. Short term palliation was as follows: dyspnea (13/15), cough (12/14), and hemoptysis (3/3). Seventeen patients were evaluated, of whom 9 (53%) showed complete response. Four patients developed local failure (only 1 of them treated with curative intent) and were salvaged with HDR-EBBT (n=1), chemotherapy (n=2), and laser (n=1). Among patients treated with curative intent, the 2-year LC and OS were 89% and 67%, respectively, and 2 out of 4 deaths were cancer-related. Late toxicity included bronchial stenosis (n=1). Only 1 patient had fatal hemoptysis and postmortem examination indicated local recurrence. Conclusion. HDR-EBBT is promising treatment with tolerable complication if used in properly selected patients.

Short-term outcome after neoadjuvant high-dose-rate endorectal brachytherapy or short-course external beam radiotherapy in resectable rectal cancer

2013 ◽  
Vol 15 (6) ◽  
pp. 662-666 ◽  
Author(s):  
C. Hesselager ◽  
T. Vuong ◽  
L. Påhlman ◽  
C. Richard ◽  
S. Liberman ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Dose Rate ◽  
External Beam Radiotherapy ◽  
High Dose Rate ◽  
High Dose ◽  
External Beam ◽  
Short Term ◽  
Term Outcome ◽  
Short Term Outcome ◽  
Short Course

Combined treatment with temporary short-term high dose rate Iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma

1997 ◽  
Vol 44 (3) ◽  
pp. 237-244 ◽  
Author(s):  
Göran Borghede ◽  
Hans Hedelin ◽  
Sten Holmäng ◽  
Karl Axel Johansson ◽  
Frank Aldenborg ◽  
...  
Keyword(s):  
Dose Rate ◽  
Prostatic Carcinoma ◽  
External Beam Radiotherapy ◽  
Combined Treatment ◽  
High Dose Rate ◽  
High Dose ◽  
External Beam ◽  
Short Term ◽  
Iridium 192

Concurrent chemoradiotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 5086-5086
Author(s):  
Yutaka Nagai ◽  
Takafumi Toita ◽  
Morihiko Inamine ◽  
Wataru Kudaka ◽  
Tomoko Nakamoto ◽  
...  
Keyword(s):  
Survival Rate ◽  
Locoregional Recurrence ◽  
Concurrent Chemoradiotherapy ◽  
External Beam Radiotherapy ◽  
Disease Free Survival ◽  
Late Toxicity ◽  
Complete Response ◽  
High Dose Rate ◽  
Intracavitary Brachytherapy ◽  
High Dose

5086 Background: Adenocarcinoma of the cervix has a worse prognosis than its squamous counterpart, particularly when cancer cells spread beyond the uterine cervix. This is derived from the observation that adenocarcinoma is less sensitive to radiotherapy (RT) and chemotherapy It is unclear whether cisplatin-based concurrent chemoradiotherapy (CCRT) has the same effect on adenocarcinoma as on squamous cell carcinoma. Methods: We retrospectively analyzed 32 patients with stage IIB–IVA cervical adenocarcinoma who were treated with RT or CCRT. Fourteen patients were treated with RT from 1983–1996, 8 with CCRT using cisplatin alone (CCRT-P) from 1997–2002, and 10 with CCRT using cisplatin+paclitaxel (CCRT-TP) after 2003. The patients were treated with external beam radiotherapy, and low-dose or high-dose rate intracavitary brachytherapy. For CCRT-P, the patients received 20 mg/m2 cisplatin for 5 days every 3 weeks, and for CCRT-TP, the patients received 50 mg/m2 cisplatin every 3 weeks and 50 mg/ m2 paclitaxel weekly. Results: A complete response was achieved in 7/14 patients in the RT, 4/8 patients in the CCRT-P, and 9/10 patients in the CCRT-TP group. Ten of the 14 patients in the RT, 7/8 patients in the CCRT-P, and 2/10 patients in the CCRT-TP group experienced locoregional recurrence. The 5-year overall survival rate in the RT, CCRT-P, and CCRT-TP groups was 7.1%, 25.0%, and 74.1%, respectively (p = 0.0094), and their central disease-free survival rate was 21.4%, 12.5%, and 78.8%, respectively (p=0.0119). The acute toxicities associated with CCRT-TP are manageable. Regarding late toxicity of CCRT-TP, no grade 3/4 adverse effect was observed. Conclusions: The present study demonstrated that CCRT-TP achieved much better local control for adenocarcinoma of the cervix, leading to a decrease in locoregional recurrence. Prospective trials in larger series of patients are urgently needed.

scholarly journals Clinical and endoscopic response to high dose rate endobronchial brachytherapy in malignant lung tumors: A single centre experience

2018 ◽  
Vol 07 (04) ◽  
pp. 267-269
Author(s):  
Sneha Dhillon ◽  
Saurabh Bansal ◽  
Girish Sindhwani ◽  
Meenu Gupta ◽  
Vipul Nautiyal ◽  
...  
Keyword(s):  
Dose Rate ◽  
Lung Tumors ◽  
High Dose Rate ◽  
P Value ◽  
High Dose ◽  
Hdr Brachytherapy ◽  
Single Centre ◽  
Short Term ◽  
Single Centre Experience ◽  
Promising Treatment

Abstract Purpose: The aim of the study was to evaluate the short-term clinical, endoscopic response, and acute toxicities in endobronchial cancer treated with high-dose-rate endobronchial brachytherapy (HDR-EB). Materials and Methods: Thirty patients of advanced endobronchial cancers were treated with HDR-EB. Brachytherapy was delivered at a depth of 1 cm from the source axis at weeks 1, 2, and 3 with 7 Gy per fraction. All patients were evaluated before treatment and at 1 month after completion of therapy. Using Speiser's scoring criteria, the severity of symptoms (dyspnea, cough, hemoptysis, and postobstructive pneumonia) and degree of obstruction were graded. Results: Symptomatic response for cough, dyspnea, and hemoptysis was seen in 88%, 75%, and 96%, respectively, with a significant P value (<0.05). Obstructive pneumonia was resolved in 94% of patients. Endoscopic response in terms of degree of obstruction was seen in 84% of patients. Acute toxicities in the form of radiation bronchitis were seen in 32% of patients, whereas 8% of patients experienced esophagitis. Bronchospasm was seen in one patient during treatment. Conclusion: HDR brachytherapy is a highly effective, safe, convenient therapy in alleviating symptoms of endobronchial obstruction with endoscopic response in the majority of cases. Thus, HDR-BT is a promising treatment for palliation of patients presenting with symptoms of endobronchial obstruction with an acceptable rate of complications.

Biochemical outcome after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy: 12 years of experience

2011 ◽  
Vol 109 (12) ◽  
pp. 1787-1793 ◽  
Author(s):  
Pedro J. Prada ◽  
Herminio González ◽  
José Fernández ◽  
Isabel Jiménez ◽  
Aránzazu Iglesias ◽  
...  
Keyword(s):  
Dose Rate ◽  
External Beam Radiotherapy ◽  
High Dose Rate ◽  
High Dose ◽  
External Beam ◽  
Years Of Experience ◽  
Intensity Modulated ◽  
Rate Intensity
Sign in / Sign up

Export Citation Format

Share Document